Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Ceftazidime nephrotoxicity in rats.

F C Luft, D W Visscher, D M Nierste

Antimicrobial Agents and Chemotherapy

|April 1, 1984

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance).

Annals of oncology : official journal of the European Society for Medical Oncology·2015

Same author

Tamoxifen suppresses histologic progression to atypia and DCIS in MCFIOAT xenografts, a model of early human breast cancer.

Breast cancer research and treatment·2001

Same author

Centrally necrotizing carcinomas of the breast: a distinct histologic subtype with aggressive clinical behavior.

The American journal of surgical pathology·2001

Same author

Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2000

Same author

Clinicopathologic significance of ductal carcinoma in situ in breast core needle biopsies with invasive cancer.

The American journal of surgical pathology·2000

Same author

Bradykinin and phorbol ester but not 5-HT2B receptor activation stimulate phospholipase D activity in the rat stomach fundus.

Progress in neuro-psychopharmacology & biological psychiatry·1999

Ceftazidime shows no increased kidney toxicity compared to cefazolin in rats. It also does not worsen tobramycin-induced kidney damage, suggesting a favorable safety profile.

Area of Science:

Pharmacology
Nephrology
Toxicology

Background:

Antibiotic-induced nephrotoxicity is a significant clinical concern.
Cephalosporins and aminoglycosides are commonly used antibiotics with potential renal side effects.
Understanding the comparative nephrotoxicity of newer agents like ceftazidime is crucial.

Purpose of the Study:

To evaluate the nephrotoxicity of ceftazidime in comparison to cefazolin and cephaloridine.
To determine if ceftazidime potentiates the nephrotoxicity of tobramycin.
To assess the renal safety profile of ceftazidime in an animal model.

Main Methods:

A rat model was used to assess kidney function and histology.
Rats were treated with ceftazidime, cefazolin, cephaloridine, and tobramycin, alone and in combination.

Related Experiment Videos

Creatinine clearance and histological examination were performed to evaluate nephrotoxicity.

Main Results:

Cephaloridine and tobramycin, when administered alone, significantly altered creatinine clearance and caused histological kidney injury.
Ceftazidime did not demonstrate greater nephrotoxicity than cefazolin.
Ceftazidime did not enhance the nephrotoxicity of tobramycin.

Conclusions:

Ceftazidime exhibits a comparable or lower nephrotoxic potential than cefazolin.
Ceftazidime does not increase the risk of kidney damage when co-administered with tobramycin.
The findings support the renal safety of ceftazidime in clinical settings.